UNSPSC 51282201: Cefotetan

This classification denotes a cephalosporin antibiotic with the molecular formula C17H17N7O8S4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48SPP0PA9Q, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl)carbonyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6alpha,7alpha))- but generally known as cefotetan, which bears US NIH Compound Identifier 50614.

UNSPSC 51282201 Cefotetan is a Commodity code that nominally covers a specific third-generation cephalosporin antibiotic, but state and local procurement activity under this code shows little relevant recent opportunity. The recent solicitations tagged with this code—Seminole County's procurement of naloxone and drug deactivation systems, the Texas HHS Commission's RFI for direct-to-manufacturer prescription programs, Tampa's bid for medical and first aid supplies for fire rescue, and Minnesota's multistate cooperative purchasing RFP for generic pharmaceuticals and OTC products—span naloxone, emergency medical consumables, and broad-based pharmacy benefit management initiatives rather than cefotetan specifically. The mismatch suggests either miscoding by the issuing bodies or that cefotetan procurement, if it occurs, is bundled with broader pharmaceutical or medical supply aggregations rather than solicited as a standalone commodity.

Activity spans multiple states and issuing-body types: Seminole County (Florida) and the City of Tampa (Florida) handle tactical medical supply procurement; the Texas Health and Human Services Commission and Minnesota Department of Administration pursue statewide or multistate pharmacy-benefit strategy through RFI and RFP vehicles; and MMCAP coordinates cooperative purchasing across Minnesota and Oregon jurisdictions. Geographic concentration appears strongest in Florida and the upper Midwest, but the solicitations address pharmaceutical and medical supply procurement broadly rather than cefotetan in isolation. The absence of recent standalone cefotetan opportunities and the general nature of the opportunities that do carry the code suggest limited direct pursuit potential under this specific commodity designation. Firms seeking pharmaceutical sales to state and local health systems should monitor broader medical supply and generic pharmaceutical RFPs—such as MMCAP's multistate cooperative contracts and state health agency direct-contracting initiatives—rather than expect regular opportunities coded specifically to individual drugs.